Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating narcolepsy, today announced that it will host a conference call and live webcast at 8:30 a.m. EST on Tuesday, November 12, 2019, to provide a corporate update and discuss the Company’s financial results for the third quarter ended September 30, 2019.
October 29, 2019
· 2 min read